Clinical Considerations in the Treatment of Acne Vulgaris and Other Inflammatory Skin Disorders: a Status Report

Dermatologic Clinics

Volumn 27, Issue 1, 2009, Pages 1-15

  Leyden, James J ^a   Del Rosso, James Q ^b   Webster, Guy F ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acne vulgaris; Anti inflammatory activity; Antibiotic resistance; Antibiotics

Indexed keywords

ADAPALENE; AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MINOCYCLINE; RETINOIC ACID; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SULFAPYRIDINE; TAZAROTENE; TETRACYCLINE;

ACNE CYSTICA; ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGRANULOCYTOSIS; ALLERGIC VASCULITIS; ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BONE MARROW DEPRESSION; BULLOUS SKIN DISEASE; CROSS RESISTANCE; DERMATITIS HERPETIFORMIS; DISEASE SEVERITY; DRESS SYNDROME; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ENTERITIS; FEVER; HEMOLYSIS; HORMONAL THERAPY; HUMAN; INFECTION SENSITIVITY; KAPOSI SARCOMA; LEPROSY; MAINTENANCE THERAPY; METHEMOGLOBINEMIA; MUCOUS MEMBRANE PEMPHIGOID; NEUROPATHY; PEMPHIGOID GESTATIONIS; PITYRIASIS LICHENOIDES; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PUSTULAR PSORIASIS; PYODERMA GANGRENOSUM; RASH; REITER SYNDROME; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SARCOIDOSIS; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VESTIBULAR DISORDER; WEBER CHRISTIAN PANNICULITIS; WEGENER GRANULOMATOSIS;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PROPIONIBACTERIUM ACNES;

EID: 54449088433     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2008.07.008     Document Type: Review

References (69)

1. Webster G.F. Acne vulgaris. BMJ 325 (2002) 475-479
2. Stern R.S. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 43 (2000) 1042-1048
3. Leyden J.J., Marples R.R., Mills O.H., et al. Gram-negative folliculitis-a complication of antibiotic therapy in acne vulgaris. Br J Dermatol 88 (1973) 533-548
4. Ross J.I., Snelling A.M., Eady E.A., et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 144 (2001) 339-346
5. Elsner P. Antimicrobials and the skin physiological and pathological flora. Curr Probl Dermatol 33 (2006) 35-41
6. Leyden J.J. Therapy for acne vulgaris. N Engl J Med 336 (1997) 1156-1162
7. Bell D.M., and Drotman D.P. Confronting antimicrobial resistance: a shared goal of family physicians and the CDC. Am Fam Physician [serial online] 59 (1999) 2097-2098. http://www.aafp.org/afp/99041ap/editorials.html Accessed August 21, 2006
8. Bachelez H., Senet P., Cadranel J., et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137 (2001) 69-73
9. Abrutyn E. New uses for old drugs. Infect Dis Clin North Am 3 (1989) 653-654
10. Roberts D.E., and Curd J.G. Sulfonamides as anti-inflammatory agents in the treatment of Wegener's granulomatosis. Arthritis Rheum 33 (1990) 1590-1593
11. Valeriano-Marcet J., and Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 151 (1991) 1649-1652
12. Webster GF. Anti-inflammatory activity of antibiotics. Presented at the Scientific Panel on Antibiotic Use in Dermatology (SPAUD) Meeting. Las Vegas, NV, April 22-23, 2006.
13. Leyden JJ. Antibiotic therapy in acne and rosacea. Presented at the Scientific Panel on Antibiotic Use in Dermatology (SPAUD) Meeting. Las Vegas, NV, April 22-23, 2006.
14. Wolf R., Matz H., Orion E., et al. Dapsone. Dermatol Online J 8 (2002) 2
15. Webster G.F., Alexander J.C., McArthur W.P., et al. Inhibition of chemiluminescence in human neutrophils by dapsone. Br J Dermatol 110 (1984) 657-663
16. Wozel G., and Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 8 (1995) 196-202
17. Modschiedler K., Weller M., Wörl P., et al. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res 292 (2000) 32-36
18. Ottonello L., Dapino P., Scirocco M.C., et al. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation?. Clin Sci (Lond) 88 (1995) 331-336
19. Sapadin A.N., and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54 (2006) 258-265
20. Amin A.R., Attur M.G., Thakker G.D., et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93 (1996) 14014-14019
21. Yrjänheikki J., Keinänen R., Pellikka M., et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95 (1998) 15769-15774
22. Skidmore R., Kovach R., Walker C., et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 139 (2003) 459-464
23. Stetler-Stevenson W.G., Liotta L.A., and Kleiner Jr. D.E. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7 (1993) 1434-1441
24. Palei A.C., Zaneti R.A., Fortuna G.M., et al. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 56 (2005) 611-617
25. Sobrin L., Liu Z., Monroy D.C., et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 41 (2000) 1703-1709
26. Golub L.M., Lee H.M., Ryan M.E., et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12 (1998) 12-26
27. Golub L.M., Ciancio S., Ramamurthy N.S., et al. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodont Res 25 (1990) 321-330
28. Grenier D., Plamondon P., Sorsa T., et al. Inhibition of proteolytic, serpinolytic and progelatinase-b activation activities of peridontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J Periodontol 73 (2002) 79-85
29. Core Technologies. CollaGenex Pharmaceuticals Inc Web site. Available at:. http://www.collagenex.com/core.asp Accessed August 18, 2006
30. O'Dell J.R., Paulsen G., Haire C.E., et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 1691-1695
31. Loo W.J., Kirtschig G., and Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Dermatol 26 (2001) 376-379
32. Helm T.N., and Lee T.C. Familial benign pemphigus (Hailey-Hailey disease). [serial online]. Updated March 28, 2007. Available at:. http://www.emedicine.com/derm/topic150.htm Accessed May 3, 2006
33. Leyden J.J., McGinley K.J., Mills O.H., et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 65 (1975) 382-384
34. Esterly N.B., Furey N.L., and Flanagan L.E. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 70 (1978) 51-55
35. Webster G.F., Leyden J.J., McGinley K.J., et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother 21 (1982) 770-772
36. Jain A., Sangal L., Basal E., et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 8 (2002) 2
37. Webster G.F., McGinley K.J., and Leyden J.J. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol 104 (1981) 453-457
38. Leyden J.J. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg 20 (2001) 139-143
39. Webster G.F., Toso S.M., and Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 130 (1994) 748-752
40. Eady E.A., Gloor M., and Leyden J.J. Propionibacterium acnes resistance: a worldwide problem. Dermatology 206 (2003) 54-56
41. Coates P., Vyakrnam S., Eady E.A., et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 146 (2002) 840-848
42. Eady E.A., Cove J.H., Holland K.T., et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 121 (1989) 51-57
43. Leyden J.J. Antibiotic resistant acne. Cutis 17 (1976) 593-606
44. Cooper A.J. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 169 (1998) 259-261
45. Tan H.H., Goh C.L., Yeo M.G., et al. Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore 30 (2001) 22-25
46. Dreno B., Reynaud A., Moyse D., et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 11 (2001) 549-553
47. Ross J.I., Snelling A.M., Carnegie E., et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 148 (2003) 467-478
48. Cunliffe W.J., Holland K.T., Bojar R., et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 24 (2002) 1117-1133
49. Leyden J.J., McGinley K.J., Cavalieri S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 8 (1983) 41-45
50. Shalita A.R., Myers J.A., Krochmal L., Clindamycin Foam Study Group, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 4 (2005) 48-56
51. Thiboutot D. Acne: 1991-2001. J Am Acad Dermatol 47 (2002) 109-117
52. Leyden J., and Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis 67 Suppl 2 (2001) 21-24
53. Ellis C.N., Leyden J., Katz H.I., et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 67 Suppl 2 (2001) 13-20
54. Leyden J.J. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 15 Suppl 3 (2001) 51-55
55. Shalita A.R., Smith E.B., and Bauer E. Topical erythromycin v clindamycin therapy for acne. a multicenter, double-blind comparison. Arch Dermatol 120 (1984) 351-355
56. Gollnick H., Cunliffe W., Berson D., et al. Global alliance to improve outcomes in acne. Management of acne: a report from a Global alliance to improve outcomes in acne. J Am Acad Dermatol 49 Suppl 1 (2003) S1-S37
57. Lookingbill D.P., Chalker D.K., Lindholm J.S., et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 37 (1997) 590-595
58. Harkaway K.S., McGinley K.J., Foglia A.N., et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 126 (1992) 586-590
59. Thiboutot D.M., Shalita A.R., Yamauchi P.S., et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 142 (2006) 597-602
60. Leyden J.J., Thiboutot D.M., Shalita A.R., et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris. Arch Dermatol 142 (2006) 605-612
61. Leyden J.J., Kaidbey K., and Gans E.H. The antimicrobial effect in vivo of minocycline, doxycycline, and tetracycline. J Dermatolog Treat 7 (1996) 223-225
62. Solodyn [package insert]. Scottsdale (AZ): Medicis Pharmaceutical Corporation; 2006.
63. Coates P., Vyakrnam S., Ravenscroft J.C., et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol 153 (2005) 1126-1136
64. Vowels B.R., Feingold D.S., Sloughfy C., et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 40 (1996) 598-604
65. Mills O., Thornsberry C., Cardin C.W., et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 82 (2002) 260-265
66. Margolis D.J., Bowe W.P., Hoffstad O., et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 141 (2005) 1132-1136
67. Levy R.M., Huang E.Y., Roling D., et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 139 (2003) 467-471
68. Adams S.J., Cunliffe W.J., and Cooke E.M. Long-term antibiotic therapy for acne vulgaris: effects on the bowel flora of patients and their relatives. J Invest Dermatol 85 (1985) 35-37
69. Miller Y.W., Eady E.A., Lacey R.W., et al. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 38 (1996) 829-837